Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Completed

Conditions studied: Prostate Cancer

In brief

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Key facts

Study ID

NCT01954004

Run by

Myriad Genetic Laboratories, Inc.

People needed

1270

Starts

2013-04-01

Expected to finish

2014-09-01

Last updated by the study team

2015-06-02

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
• Clinically localized (no evidence on clinical or imaging studies of advanced disease).
• No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
• Sufficient amount of tissue remains from biopsy to perform genomic testing.

You may not qualify if…

• Patients with a known history of hypogonadism

Where it is running

• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.